{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:02:07Z","timestamp":1786975327890,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41397-021-00235-7","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T11:07:10Z","timestamp":1618312030000},"page":"586-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2837-5248","authenticated-orcid":false,"given":"Stefania","family":"Cheli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-8441","authenticated-orcid":false,"given":"Annalisa","family":"De Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-7969","authenticated-orcid":false,"given":"Marta","family":"Fusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Minisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-6530","authenticated-orcid":false,"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Meraviglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-3663","authenticated-orcid":false,"given":"Cristina","family":"Montrasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"235_CR1","doi-asserted-by":"publisher","first-page":"232595822091923","DOI":"10.1177\/2325958220919231","volume":"19","author":"C Wassner","year":"2020","unstructured":"Wassner C, Bradley N, Lee Y. A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020;19:2325958220919231. https:\/\/doi.org\/10.1177\/2325958220919231.","journal-title":"J Int Assoc Provid AIDS Care."},{"key":"235_CR2","unstructured":"EACS. Guidelines, version 10.0, 2019. https:\/\/www.eacsociety.org\/files\/2019_guidelines-10.0%20final.pdf."},{"key":"235_CR3","unstructured":"US HIV treatment guidelines. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/0."},{"key":"235_CR4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1089\/apc.2019.0236","volume":"33","author":"KJ Kauppinen","year":"2019","unstructured":"Kauppinen KJ, Kivel\u00e4 P, Sutinen J. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide significantly worsens the lipid profile in a real-world setting. AIDS Patient Care STDS. 2019;33:500\u20136. https:\/\/doi.org\/10.1089\/apc.2019.0236.","journal-title":"AIDS Patient Care STDS."},{"key":"235_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","volume":"4","author":"A Hill","year":"2018","unstructured":"Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad. 2018;4:72\u20139.","journal-title":"J Virus Erad"},{"key":"235_CR6","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/QAD.0000000000002699","volume":"34","author":"V Pilkington","year":"2020","unstructured":"Pilkington V, Hughes SL, Pepperrell T, McCann K, Gotham D, Pozniak AL, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14\u200a894 patients across 14 trials. AIDS. 2020;34:2259\u201368. https:\/\/doi.org\/10.1097\/QAD.0000000000002699.","journal-title":"AIDS."},{"key":"235_CR7","unstructured":"FDA. Integrated review for Pifeltro and Delstrigo approval. 2018. https:\/\/www.fda.gov\/media\/128270\/download."},{"key":"235_CR8","unstructured":"EMA. Assessment report for Delstrigo. 2018. EMA\/874672\/2018. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/delstrigo-epar-public-assessment-report_en.pdf."},{"key":"235_CR9","doi-asserted-by":"publisher","unstructured":"Pham HT, Xiao MA, Principe MA, Wong A, Mespl\u00e8de T. Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. Drugs Context. 2020;9:2019-11-4. https:\/\/doi.org\/10.7573\/dic.2019-11-4.","DOI":"10.7573\/dic.2019-11-4"},{"key":"235_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","volume":"58","author":"A Boyle","year":"2019","unstructured":"Boyle A, Moss CE, Marzolini C, Khoo S. Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine. Clin Pharmacokinet. 2019;58:1553\u201365. https:\/\/doi.org\/10.1007\/s40262-019-00806-9.","journal-title":"Clin Pharmacokinet"},{"key":"235_CR11","doi-asserted-by":"publisher","first-page":"248.","DOI":"10.3389\/fphar.2014.00248","volume":"5","author":"DM Moss","year":"2014","unstructured":"Moss DM, Neary M, Owen A. The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol. 2014;5:248. https:\/\/doi.org\/10.3389\/fphar.2014.00248.","journal-title":"Front Pharmacol."},{"key":"235_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/labinvest.2009.14","volume":"89","author":"JJ Kohler","year":"2009","unstructured":"Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Investig. 2009;89:513\u20139. https:\/\/doi.org\/10.1038\/labinvest.2009.14.","journal-title":"Lab Investig."},{"key":"235_CR13","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1086\/598507","volume":"48","author":"S Rodr\u00edguez-N\u00f3voa","year":"2009","unstructured":"Rodr\u00edguez-N\u00f3voa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108\u201316. https:\/\/doi.org\/10.1086\/598507.","journal-title":"Clin Infect Dis."},{"key":"235_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/infdis\/jir215","volume":"204","author":"SP Pushpakom","year":"2011","unstructured":"Pushpakom SP, Liptrott NJ, Rodr\u00edguez-N\u00f3voa S, Labarga P, Soriano V, Albalater M, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011;204:145\u201353. https:\/\/doi.org\/10.1093\/infdis\/jir215.","journal-title":"J Infect Dis."},{"key":"235_CR15","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1128\/AAC.04930-14","volume":"59","author":"K Rungtivasuwan","year":"2015","unstructured":"Rungtivasuwan K, Avihingsanon A, Thammajaruk N, Mitruk S, Burger DM, Ruxrungtham K, et al. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. Antimicrob Agents Chemother. 2015;59:3240\u20135. https:\/\/doi.org\/10.1128\/AAC.04930-14.","journal-title":"Antimicrob Agents Chemother."},{"key":"235_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41397-018-0064-y","volume":"19","author":"A Calcagno","year":"2019","unstructured":"Calcagno A, Fiuman\u00f2 M, Zugna D, Cusato J, Montrucchio C, Marinaro L, et al. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization? Pharmacogenomics J. 2019;19:65\u201371. https:\/\/doi.org\/10.1038\/s41397-018-0064-y.","journal-title":"Pharmacogenomics J."},{"key":"235_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/tpj.2015.71","volume":"16","author":"A Calcagno","year":"2016","unstructured":"Calcagno A, Cusato J, Marinaro L, Trentini L, Alcantarini C, Mussa M, et al. Clinical pharmacology of tenofovir clearance: a pharmacokinetic\/pharmacogenetic study on plasma and urines. Pharmacogenomics J. 2016;16:514\u20138. https:\/\/doi.org\/10.1038\/tpj.2015.71.","journal-title":"Pharmacogenomics J."},{"key":"235_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/01.qai.0000225013.53568.69","volume":"42","author":"PL Anderson","year":"2006","unstructured":"Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006;42:441\u20139. https:\/\/doi.org\/10.1097\/01.qai.0000225013.53568.69.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"235_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2217\/pgs-2017-0128","volume":"18","author":"K Rungtivasuwan","year":"2017","unstructured":"Rungtivasuwan K, Avihingsanon A, Thammajaruk N, Mitruk S, Burger DM, Ruxrungtham K, et al. Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients. Pharmacogenomics. 2017;18:1481\u201390. https:\/\/doi.org\/10.2217\/pgs-2017-0128.","journal-title":"Pharmacogenomics."},{"key":"235_CR20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/qai.0b013e31815e7478","volume":"47","author":"JJ Kiser","year":"2008","unstructured":"Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:298\u2013303. https:\/\/doi.org\/10.1097\/qai.0b013e31815e7478.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"Suppl.","key":"235_CR21","first-page":"1","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3 Suppl.:1\u2013150.","journal-title":"Kidney Int."},{"key":"235_CR22","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/QAD.0b013e32833202e2","volume":"24","author":"S Rodr\u00edguez-N\u00f3voa","year":"2010","unstructured":"Rodr\u00edguez-N\u00f3voa S, Labarga P, D\u2019Avolio A, Barreiro P, Albalate M, Vispo E, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24:1064\u20136. https:\/\/doi.org\/10.1097\/QAD.0b013e32833202e2.","journal-title":"AIDS."},{"key":"235_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/QAI.0b013e31827ce4ee","volume":"62","author":"I Poizot-Martin","year":"2013","unstructured":"Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, et al. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2013;62:375\u201380. https:\/\/doi.org\/10.1097\/QAI.0b013e31827ce4ee.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"235_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3851\/IMP2761","volume":"19","author":"M Ezinga","year":"2014","unstructured":"Ezinga M, Wetzels JF, Bosch ME, van der Ven AJ, Burger DM. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration. Antivir Ther. 2014;19:765\u201371. https:\/\/doi.org\/10.3851\/IMP2761.","journal-title":"Antivir Ther."},{"key":"235_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med."},{"key":"235_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/QAI.0000000000001558","volume":"77","author":"D Cattaneo","year":"2018","unstructured":"Cattaneo D, Minisci D, Baldelli S, Mazzali C, Giacomelli A, Milazzo L, et al. Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF. J Acquir Immune Defic Syndr. 2018;77:86\u201392. https:\/\/doi.org\/10.1097\/QAI.0000000000001558.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"235_CR27","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/508546","volume":"194","author":"H Izzedine","year":"2006","unstructured":"Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194:1481\u201391. https:\/\/doi.org\/10.1086\/508546.","journal-title":"J Infect Dis"},{"key":"235_CR28","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1128\/AAC.00251-06","volume":"50","author":"AS Ray","year":"2006","unstructured":"Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297\u2013304. https:\/\/doi.org\/10.1128\/AAC.00251-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"235_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/FPC.0000000000000110","volume":"25","author":"A Dahlin","year":"2015","unstructured":"Dahlin A, Wittwer M, de la Cruz M, Woo JM, Bam R, Scharen-Guivel V, et al. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet Genom. 2015;25:82\u201392. https:\/\/doi.org\/10.1097\/FPC.0000000000000110.","journal-title":"Pharmacogenet Genom."},{"key":"235_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/QAD.0000000000000901","volume":"30","author":"JL Casado","year":"2016","unstructured":"Casado JL, Ba\u00f1\u00f3n S, Santiuste C, Serna J, Guzman P, Tenorio M, et al. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir. AIDS. 2016;30:231\u20139. https:\/\/doi.org\/10.1097\/QAD.0000000000000901.","journal-title":"AIDS."},{"key":"235_CR31","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1515\/cclm-2018-0181","volume":"56","author":"I Prodan \u017ditnik","year":"2018","unstructured":"Prodan \u017ditnik I, \u010cerne D, Mancini I, Simi L, Pazzagli M, Di Resta C, et al. Behalf of EFLM\/ESPT working group of Personalised Laboratory Medicine on. Personalized laboratory medicine: a patient-centered future approach. Clin Chem Lab Med. 2018;56:1981\u201391. https:\/\/doi.org\/10.1515\/cclm-2018-0181.","journal-title":"Clin Chem Lab Med."}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00235-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00235-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00235-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T08:07:52Z","timestamp":1632211672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00235-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["235"],"URL":"https:\/\/doi.org\/10.1038\/s41397-021-00235-7","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"15 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data used for this study were collected for clinical purposes and were previously anonymised, according to the requirements set by the Italian Data Protection Code (leg. decree 196\/2003) and by the general authorizations issued by the Data Protection Authority. Approval by Ethics Committee was unnecessary because, under Italian law, such an approval is required only in the hypothesis of prospective clinical trials on medical products for clinical use (art. 6 and art. 9, leg. decree 211\/2003). Each patient included in this study provided a written informed consent for genetic testing and publication of clinical data for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}